Genes, chromosomes & cancer · 2026
Integrated Genomic Profiling of PTEN and TP53 in Cervical Neuroendocrine Carcinoma: Synergistic Roles With HER2/KRAS/PIK3CA and Implications for Precision Oncology.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shen Huang-Pin, Lee Ming-Yung, Lee Yi-Ju, Chen An-Chi, Chen Chi-Kuan, Chao Wan-Ru, Han Chih-Ping
Аннотация
BACKGROUND: Neuroendocrine carcinoma (NEC) of the uterine cervix is a rare, highly aggressive malignancy with a poor prognosis. Expanding upon our previous work, which identified frequent mutations in HER2, KRAS, and PIK3CA in this disease, we sought to refine the genomic landscape by characterizing alterations in TP53 and PTEN, and their relationships with these oncogenic drivers.
METHODS: Genomic DNA from 12 cervical NECs with ≥ 50% tumor cellularity underwent targeted next-generation sequencing (NGS) using the Qiagen GeneRead DNAseq Targeted Panels V2. Variants were filtered against COSMIC and ClinVar, and the pathogenicity of missense changes was assessed with PolyPhen-2, with scores > 0.85 considered probably damaging.
RESULTS: PTEN alterations were identified in 25.0% (3/12) of tumors, encompassing four truncating mutations (p.W111*, p.Q171*, p.Q245*, p.R335*) and three missense variants (p.R130Q, p.E394G, p.D395V). A TP53 DNA-binding domain hotspot mutation, p.R273H, was detected in 8.33% (1/12). These tumor-suppressor lesions frequently co-occurred with oncogenic driver mutations, including HER2/PTEN (8.33%), PIK3CA/PTEN (8.33%), and a KRAS/PTEN/TP53 "triple-hit" (8.33%), underscoring multipathway genomic complexity.
CONCLUSIONS: Our findings suggest a genomic landscape consistent with a multihit hypothesis in cervical NEC, in which disruption of the reciprocal tumor-suppressive PTEN-p53 axis (25.0% and 8.33%, respectively) co-occurs with oncogenic HER2, KRAS, or PIK3CA alterations. Structural mapping indicates that TP53 p.R273H gain-of-function mutations and PTEN loss-of-function variants are associated with sustained PI3K/AKT/mTOR pathway activation. Integrating TP53 and PTEN status with oncogenic driver profiling may facilitate the identification of biologically defined subsets and inform precision therapeutic strategies for cervical NEC.
METHODS: Genomic DNA from 12 cervical NECs with ≥ 50% tumor cellularity underwent targeted next-generation sequencing (NGS) using the Qiagen GeneRead DNAseq Targeted Panels V2. Variants were filtered against COSMIC and ClinVar, and the pathogenicity of missense changes was assessed with PolyPhen-2, with scores > 0.85 considered probably damaging.
RESULTS: PTEN alterations were identified in 25.0% (3/12) of tumors, encompassing four truncating mutations (p.W111*, p.Q171*, p.Q245*, p.R335*) and three missense variants (p.R130Q, p.E394G, p.D395V). A TP53 DNA-binding domain hotspot mutation, p.R273H, was detected in 8.33% (1/12). These tumor-suppressor lesions frequently co-occurred with oncogenic driver mutations, including HER2/PTEN (8.33%), PIK3CA/PTEN (8.33%), and a KRAS/PTEN/TP53 "triple-hit" (8.33%), underscoring multipathway genomic complexity.
CONCLUSIONS: Our findings suggest a genomic landscape consistent with a multihit hypothesis in cervical NEC, in which disruption of the reciprocal tumor-suppressive PTEN-p53 axis (25.0% and 8.33%, respectively) co-occurs with oncogenic HER2, KRAS, or PIK3CA alterations. Structural mapping indicates that TP53 p.R273H gain-of-function mutations and PTEN loss-of-function variants are associated with sustained PI3K/AKT/mTOR pathway activation. Integrating TP53 and PTEN status with oncogenic driver profiling may facilitate the identification of biologically defined subsets and inform precision therapeutic strategies for cervical NEC.